M&A / Deals Odyssey launches upsized $279M IPO, Seaport docks on Nasdaq BioSpaceAnalysts are cautiously optimistic about an IPO rebound for biopharma.Read full story pharminent May 8, 2026 (Last updated: May 10, 2026) BioSpace Analysts are cautiously optimistic about an IPO rebound for biopharma. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Novo’s CEO champions “record-breaking start” for Wegovy pill in US marketNext: Biogen, Eisai hit with 3-month delay for starting SubQ Alzheimer’s therapy Related Stories M&A / Deals Fulcrum exploring a potential sale after FDA sidelined its sickle cell drug pharminent June 2, 2026 M&A / Deals CordenPharma inks AmbioPharm buyout to continue peptide production expansion pharminent June 1, 2026 M&A / Deals Servier wagers $2.65bn on Edgewise muscular dystrophy drug pharminent June 1, 2026
